Recent Updates
Recently added Catalysts
CBLL Positive Sentiment

Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference

Key Takeaway: Ceribell, Inc. announced that CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will highlight the company's innovative Ceribell System, which is designed for rapid diagnosis and monitoring of neurological conditions. A webcast of the presentation will be available on their website.
Price reaction · baseline $17.83 (2026-07-28 close) · hit after-hours · 1 other CBLL headline(s) in the window, move may be shared
day 0 close · peak
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell is participating in a notable industry conference.
  • The company is focused on advancing neurological care.
  • The Ceribell System is FDA-cleared for critical applications.

Full Press Release Details

SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity 46 th Annual Growth Conference in Boston. The fireside chat will take place on Wednesday, August 12, 2026, at 6:00 a.m. Pacific Daylight Time / 9:00 a.m. Eastern Daylight Time.

Event: Canaccord Genuity 46 th Annual Growth Conference Date: Wednesday, August 12, 2026 Time: 6:00 a.m. PDT / 9:00 a.m. EDT

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc. Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact Brian Johnston Gilmartin Group Investors@ceribell.com

Media Contact Brian Price Press@ceribell.com

Frequently Asked Questions

When is Ceribell's participation in the conference?

Ceribell will participate in the conference on August 12, 2026.

Who will represent Ceribell at the conference?

CFO Scott Blumberg will represent Ceribell at the event.

What is the focus of Ceribell's technology?

Ceribell focuses on diagnosing and managing serious neurological conditions.

Where can I watch the conference presentation?

The presentation will be available on Ceribell's Investor Relations website.

Last updated: Jul 28, 2026